Oncology Division Department of Surgery Cipto Mangunkusumo National Hospital, Faculty of Medicine Universitas Indonesia, Jakarta 10430, Indonesia.
Department of Surgical Oncology, Dharmais Hospital, National Cancer Hospital, Jakarta 11420, Indonesia.
Int J Surg Oncol. 2020 Jul 3;2020:7863243. doi: 10.1155/2020/7863243. eCollection 2020.
Breast cancer is the most common cancer with an increasing incidence in Asia. About 20% of all breast cancers are triple-negative breast cancers (TNBCs). BCSC is a subset of tumor cells that has stem cell-like characteristics, such as a high capacity for self-renewal and tumor initiation, which implies that BCSC may cause aggressiveness of TNBC. ALDH1 has a role in early stem cell differentiation through its function in the oxidation of retinol to retinoic acid, proposed to be a strong candidate for breast cancer stem cells. Various studies have shown that ALDH1 is one of the markers of CSC that can be used as a prognosis indicator because it can be a biological marker for poor prognostic factors in TNBC. This study assessed the prognostic survival rate with a retrospective cohort method in TNBC patients. A total of 54 of 55 patients treated at RSCM were tested for the expression of ALDH1 through an immunohistochemistry assay of breast cancer tissue using ALDH1 staining. Survival analysis was done to obtain the prognostic data of ALDH1. Positive ALDH1 expression was obtained at 38.89% in TNBC patients. One-year survival and three years of survival in TNBC patients with positive ALDH1 expression were 42.9% and 33.3%, respectively. In this study, ALDH1 can be used as a poor survival prognostic factor with HR 2.636 and value 0.013. The conclusion of this study is that ALDH1 can be used as a poor prognostic factor in TNBC patients although it cannot be an independent prognostic factor.
乳腺癌是亚洲发病率不断上升的最常见癌症之一。约 20%的乳腺癌为三阴性乳腺癌（TNBC）。BCSC 是肿瘤细胞的一个亚群，具有干细胞样特征，如自我更新和肿瘤起始的高能力，这意味着 BCSC 可能导致 TNBC 的侵袭性。ALDH1 在早期干细胞分化中发挥作用，通过其将视黄醇氧化为视黄酸的功能，被提议成为乳腺癌干细胞的一个强有力候选物。多项研究表明，ALDH1 是 CSC 的标志物之一，可用作预后指标，因为它可能是 TNBC 中预后不良因素的生物学标志物。本研究采用回顾性队列方法评估 TNBC 患者的预后生存率。对在 RSCM 接受治疗的 55 例患者中的 54 例进行了 ALDH1 表达检测，通过对乳腺癌组织进行 ALDH1 染色的免疫组织化学检测。进行生存分析以获得 ALDH1 的预后数据。在 TNBC 患者中，ALDH1 阳性表达率为 38.89%。在 ALDH1 阳性表达的 TNBC 患者中，1 年生存率和 3 年生存率分别为 42.9%和 33.3%。在这项研究中，ALDH1 可以作为预后不良的预测因子，HR 为 2.636，p 值为 0.013。本研究的结论是，ALDH1 可以作为 TNBC 患者的不良预后因素，尽管它不能作为独立的预后因素。
